Pimozide

Pimozide
Clinical data
Trade names	Orap
AHFS/Drugs.com	Monograph
MedlinePlus	a686018
License data	US FDA: Pimozide;
Pregnancy; category	AU: B1;
Routes of; administration	Oral
Drug class	Typical antipsychotic
ATC code	N05AG02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); US: ℞-only;
Pharmacokinetic data
Bioavailability	40-50%
Metabolism	CYP3A4, CYP1A2 and CYP2D6
Elimination half-life	55 hours (adults), 66 hours (children)
Excretion	Urine
Identifiers
	IUPAC name 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazole-2-one;
CAS Number	2062-78-4 ;
PubChem CID	16362;
IUPHAR/BPS	90;
DrugBank	DB01100 ;
ChemSpider	15520 ;
UNII	1HIZ4DL86F;
KEGG	D00560 ;
ChEBI	CHEBI:8212 ;
ChEMBL	ChEMBL1423 ;
CompTox Dashboard (EPA)	DTXSID8023474 ;
ECHA InfoCard	100.016.520
Chemical and physical data
Formula	C28H29F2N3O
Molar mass	461.557 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc(cc1)C(c2ccc(F)cc2)CCCN5CCC(N4c3ccccc3NC4=O)CC5;
	InChI InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34) ; Key:YVUQSNJEYSNKRX-UHFFFAOYSA-N ;
	(verify)

Pimozide (sold under the brand name Orap) is a neuroleptic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special indication for Tourette syndrome and resistant tics.